Dwight St Clair, DO
Psychiatry · Wichita, KSNPI 1437175254
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 57.0% of the total. Reporting peaked in 2023 at $6,479 and has fallen 87.6% since, to $803 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $37.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
- Lundbeck LLC$1K
- Vanda Pharmaceuticals Inc.$948
- Teva Pharmaceuticals USA, Inc.$661
- Neurocrine Biosciences, Inc.$561
- Alkermes, Inc.$528
- plus $4K from 23 others
Across 5 payments — averaging $1745.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
- Biogen$3K
- Biohaven Pharmaceutical Holding Company Ltd.$748
- Takeda Pharmaceuticals U.S.A., Inc.$78
What the payments were for
- Speaking & faculty fees$9,66052%
- Travel & lodging$3072%
- Food & beverage$8,49046%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $10,518 |
| Lundbeck LLC | 50 | $1,015 |
| Vanda Pharmaceuticals Inc. | 43 | $948 |
| Teva Pharmaceuticals USA, Inc. | 38 | $661 |
| Neurocrine Biosciences, Inc. | 36 | $561 |
| Alkermes, Inc. | 27 | $528 |
| Otsuka America Pharmaceutical, Inc. | 29 | $527 |
| Sunovion Pharmaceuticals Inc. | 35 | $451 |
| AbbVie(2 entities) | 23 | $425 |
| Eisai Inc. | 33 | $412 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $368 |
| Neos Therapeutics, LP | 25 | $334 |
| Merck | 17 | $264 |
| Johnson & Johnson | 14 | $258 |
| Ironshore Pharmaceuticals Inc. | 6 | $237 |
| Axsome Therapeutics, Inc. | 9 | $200 |
| Idorsia Pharmaceuticals US Inc | 8 | $133 |
| Bausch Health US, LLC | 8 | $126 |
| Avanir Pharmaceuticals, Inc. | 6 | $100 |
| Corium, LLC | 4 | $86 |
| Adlon Therapeutics L.p. | 5 | $68 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Almatica Pharma LLC | 2 | $38 |
| Alfasigma USA, Inc. | 2 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Biogen | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,463 in reported general payments places this provider in the 90th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $64,210 |
| RexultiBrexpiprazole | 16 | $34,719 |
| Seroquel XrQuetiapine Fumarate | 13 | $21,098 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $10,466 |
| DayvigoLemborexant | 11 | $5,021 |
| Lamotrigine OdtLamotrigine | 14 | $4,443 |
| Fluvoxamine Maleate | 59 | $2,686 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 48 | $2,404 |
| Olanzapine | 59 | $1,831 |
| Duloxetine Hcl | 86 | $1,780 |
| Bupropion XlBupropion Hcl | 88 | $1,536 |
| Carbamazepine | 48 | $1,503 |
| Quetiapine Fumarate | 120 | $1,502 |
| Ziprasidone Hcl | 18 | $1,430 |
| Oxazepam | 20 | $1,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $661 | $64,21012 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $527 | $34,71916 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $100 | $10,46612 claims |
| Eisai Inc.Dayvigo | $412 | $5,02111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Wichita
- Sheldon PreskornWichita$498K
- Heidi OgdenWichita$55K
- Ralph BharatiWichita$26K
- Paul MurphyWichita$19K
- Mukhtar ShahWichita$12K
- Rex LearWichita$11K
- Lin XuWichita$9K
- Mercedes PeralesWichita$8K
- Jasmine KaurWichita$6K
- Peter SeilerWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.